参松养心胶囊联合琥珀酸美托洛尔治疗冠心病心绞痛的临床疗效

Clinical Efficacy of Shensong Yangxin Capsule Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease and Angina Pectoris

目的探讨参松养心胶囊联合美托洛尔治疗冠心病心绞痛的临床疗效。方法选取2018年4月—2020年4月于该院就诊的60例冠心病心绞痛患者,按随机数字表法分为两组,各30例。对照组采用美托洛尔治疗,观察组加用参松养心胶囊治疗。比较两组临床疗效、24 h动态心电图指标、血清学指标、心绞痛症状和心肌缺血状况,并观察不良反应发生情况。结果观察组总有效率为93.33%,高于对照组的73.33%,差异有统计学意义(χ^2=4.320,P=0.038);观察组治疗后24 h室性期前收缩和室上性期前收缩次数为(1433.52±106.85)次、(535.14±93.58)次,少于对照组的(1632.48±126.48)次、(635.76±99.54)次,差异有统计学意义(t=6.582、4.034,P<0.05);观察组治疗后红细胞比容(HCT)、组织蛋白酶S(Cat S)水平为(0.41±0.03)、(18.61±2.17)μg/L,低于对照组的(0.45±0.05)、(21.05±2.24)μg/L,差异有统计学意义(t=3.757、4.285,P<0.05);观察组心绞痛持续时间为(3.05±0.62)min,短于对照组的(4.39±0.71)min,心绞痛1周发作频率为(2.03±0.41)次,少于对照组的(3.25±0.53)次,差异有统计学意义(t=7.786、9.972,P<0.05);两组24 h心肌缺血状况比较,差异无统计学意义(χ^2=0.000,P=1.000);两组均无严重不良反应。结论参松养心胶囊联合美托洛尔可减少心绞痛发作次数,改善24 h动态心电图指标,降低血清内HCT、Cat S表达,稳定病情进展,安全可靠。

Objective To explore the clinical efficacy of Shensongyangxin capsule combined with metoprolol in the treatment of angina pectoris of coronary heart disease.Methods A total of 60 patients with coronary heart disease and angina pectoris in the hospital from April 2018 to April 2020 were selected and divided into two groups according to the random number table method,with 30 cases in each group.The control group was treated with metoprolol,and the observation group was treated with Shensong Yangxin capsules.The clinical efficacy,24 h dynamic electrocardiogram indicators,serological indicators,angina pectoris symptoms and myocardial ischemia were compared between the two groups,and adverse reactions were observed.Results The total effective rate of the observation group was 93.33%,which was higher than 73.33%of the control group,the difference was statistically significant(χ^2=4.320,P=0.038);the number of ventricular premature contractions and supraventricular premature contractions 24 h after treatment in the observation group was(1433.52±106.85)times,(535.14±93.58)times,less than(1632.48±126.48)times and(635.76±99.54)times in the control group,the difference was statistically significant(t=6.582,4.034,P<0.05);the hematocrit(HCT)and cathepsin S(Cat S)levels of the observation group after treatment were(0.41±0.03)and(18.61±2.17)μg/L,which were lower than the control group(0.45±0.05),(21.05±2.24)μg/L,the difference was statistically significant(t=3.757,4.285,P<0.05);the duration of angina in the observation group was(3.05±0.62)min,which was shorter than that in the control group(4.39±0.71)min,the frequency of angina pectoris in one week was(2.03±0.41)times,which was less than(3.25±0.53)times in the control group,the difference was statistically significant(t=7.786,9.972,P<0.05).There was not statistical difference in the status of myocardial ischemia at 24 hours(χ^2=0.000,P=1.000);there were no serious adverse reactions in the two groups.Conclusion Shensong Yangxin capsule combined with metoprolol can reduce the number of angina pectoris,improve 24h dynamic electrocardiogram index,reduce the expression of HCT and Cat S in serum,stabilize disease progression,and be safe and reliable.